Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 182 Leukemia 128 Lymphoma 91 Leukemia, Myeloid, Acute 83 Myelodysplastic Syndromes 64 Burkitt Lymphoma 59 Lymphoma, Non-Hodgkin 53 Lymphoma, Large B-Cell, Diffuse 42 Leukemia, Myeloid, Accelerated Phase 39 Leukemia, Lymphocytic, Chronic, B-Cell 39 Lymphoma, Mantle-Cell 38 Hodgkin Disease 38 Graft vs Host Disease 36 Blast Crisis 35 Congenital Abnormalities 34 Multiple Myeloma 33 Lymphoma, Follicular 33 Leukemia, Myeloid, Chronic-Phase 33 Myeloproliferative Disorders 32 Recurrence 30 Breast Neoplasms 29 Leukemia, Myelomonocytic, Chronic 28 Primary Myelofibrosis 26 Lymphoma, Large-Cell, Immunoblastic 26 Lymphoma, B-Cell, Marginal Zone 25 Neoplasms, Plasma Cell 22 Osteosarcoma 21 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 20 Leukemia, Biphenotypic, Acute 20

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Survival Without Progression × Methotrexate × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡